NVO Jul 2024 155.000 call

Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market

GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter joins Catalysts to discuss the state of the weight-loss market and the potential headwinds for these pharmaceutical companies. "There's been a duopoly situation via Lilly and Novo," Richter explains. She points to Zealand (ZEAL.CO), Amgen (AMGN), and Regeneron (REGN) as companies she's watching that could become competitors in the weight-loss market. She notes that Eli Lilly and Novo Nordisk are facing limited supply as demand skyrockets. The two pharmaceutical companies have to make significant investments to expand manufacturing capabilities, and Richter explains, "I think what everybody realizes is based on the opportunity, the investment in manufacturing and supply has to come in much earlier than perhaps thought before." For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl